Novo Nordisk To Up Production Capacity As Parent Buys Catalent
Published
Shares in Novo Nordisk rose after its parent, Novo Holdings, said it has agreed to by contract drug manufacturer Catalent for $11.5 billion in cash.
Full ArticlePublished
Shares in Novo Nordisk rose after its parent, Novo Holdings, said it has agreed to by contract drug manufacturer Catalent for $11.5 billion in cash.
Full ArticleThe sale of listed contract drugmaker Catalent to the parent of Novo Nordisk this week demonstrates the importance for big pharma..